Attached files

file filename
8-K - LIVE FILING - IMMUNE PHARMACEUTICALS INChtm_46824.htm
EX-16.1 2 exhibit1.htm EX-16.1 EX-16.1

January 7, 2013

Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561

Dear Sirs/Madams:

We have read Item 4.1 of EpiCept Corporation’s Form 8-K dated January 7, 2013, and we agree with the statements made therein.

Yours truly,

/s/ Deloitte & Touche LLP